Literature DB >> 15700180

Reduced phospholipid breakdown in Alzheimer's brains: a 31P spectroscopy study.

Orestes V Forlenza1, Priscilla Wacker, Paula V Nunes, Juliana Yacubian, Claudio C Castro, Maria C G Otaduy, Wagner F Gattaz.   

Abstract

BACKGROUND: Abnormalities of membrane phospholipid metabolism have been described in Alzheimer's disease (AD). We investigated, with the aid of (31)P magnetic resonance spectroscopy, the in vivo intracerebral availability of phosphomonoesters (PME) and phosphodiesters (PDE) in patients with AD.
METHODS: Eighteen outpatients with mild or moderate probable AD and 16 nondemented elderly volunteers were assessed with the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) and its cognitive subscale of the CAMDEX schedule (CAMCOG). Scans were performed on a 1.5 T magnetic resonance imager addressing a 40-cm(3) voxel in the left prefrontal cortex. Main outcome measures were mean relative peak areas of PME and PDE, which provide an estimate of membrane phospholipid metabolism.
RESULTS: PME resonance and the PME/PDE ratio were increased in AD patients as compared to controls (p<0.05). PME was negatively correlated with global cognitive performance as shown by the Mini-Mental State Examination (r(s)=-0.36, p=0.05) and CAMCOG scores (r(s)=-0.49, p=0.007), as well as with discrete neuropsychological functions, namely, memory (r(s)=-0.53, p=0.004), visual perception (r(s)=-0.54, p=0.003), orientation (r(s)=-0.36, p=0.05), and abstract thinking (r(s)=-0.48, p=0.01).
CONCLUSIONS: We provide evidence of reduced membrane phospholipid breakdown in the prefrontal cortex of mild and moderately demented AD patients. These abnormalities correlate with neuropsychological deficits that are characteristic of AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700180     DOI: 10.1007/s00213-005-2168-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge

Authors: 
Journal:  J Magn Reson       Date:  1997-11       Impact factor: 2.229

2.  Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy.

Authors:  P A Bottomley; J P Cousins; D L Pendrey; W A Wagle; C J Hardy; F A Eames; R J McCaffrey; D A Thompson
Journal:  Radiology       Date:  1992-06       Impact factor: 11.105

3.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

4.  Calcium-sensitive cytosolic phospholipase A2 (cPLA2) is expressed in human brain astrocytes.

Authors:  D T Stephenson; J V Manetta; D L White; X G Chiou; L Cox; B Gitter; P C May; J D Sharp; R M Kramer; J A Clemens
Journal:  Brain Res       Date:  1994-02-21       Impact factor: 3.252

5.  Increased platelet phospholipase A2 activity in schizophrenia.

Authors:  W F Gattaz; A Schmitt; A Maras
Journal:  Schizophr Res       Date:  1995-07       Impact factor: 4.939

6.  CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia.

Authors:  M Roth; E Tym; C Q Mountjoy; F A Huppert; H Hendrie; S Verma; R Goddard
Journal:  Br J Psychiatry       Date:  1986-12       Impact factor: 9.319

7.  Synthesis of acetylcholine from choline derived from phosphatidylcholine in a human neuronal cell line.

Authors:  J K Blusztajn; M Liscovitch; U I Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

8.  Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease.

Authors:  J W Pettegrew; K Panchalingam; J Moossy; J Martinez; G Rao; F Boller
Journal:  Arch Neurol       Date:  1988-10

9.  Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease.

Authors:  C Mulder; L-O Wahlund; T Teerlink; M Blomberg; R Veerhuis; G J van Kamp; P Scheltens; P G Scheffer
Journal:  J Neural Transm (Vienna)       Date:  2003-08       Impact factor: 3.575

10.  Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease.

Authors:  W F Gattaz; N J Cairns; R Levy; H Förstl; D F Braus; A Maras
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

View more
  13 in total

Review 1.  Platelet biomarkers in Alzheimer's disease.

Authors:  Leda L Talib; Helena Pg Joaquim; Orestes V Forlenza
Journal:  World J Psychiatry       Date:  2012-12-22

2.  Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients.

Authors:  L L Talib; S R Hototian; H P G Joaquim; O V Forlenza; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-04-29       Impact factor: 5.270

Review 3.  The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer's disease.

Authors:  O V Forlenza; E L Schaeffer; W F Gattaz
Journal:  J Neural Transm (Vienna)       Date:  2006-11-27       Impact factor: 3.575

Review 4.  Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies.

Authors:  Tao Song; Xiaopeng Song; Chenyawen Zhu; Regan Patrick; Miranda Skurla; Isabella Santangelo; Morgan Green; David Harper; Boyu Ren; Brent P Forester; Dost Öngür; Fei Du
Journal:  Ageing Res Rev       Date:  2021-10-29       Impact factor: 10.895

Review 5.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

6.  Low platelet iPLA₂ activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.

Authors:  Wagner F Gattaz; Leda L Talib; Evelin L Schaeffer; Breno S Diniz; Orestes V Forlenza
Journal:  J Neural Transm (Vienna)       Date:  2013-09-15       Impact factor: 3.575

Review 7.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

Review 8.  MR spectroscopy in neurodegenerative disease.

Authors:  W R Wayne Martin
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

9.  The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial.

Authors:  Anne Rijpma; Marinette van der Graaf; Marieke M Lansbergen; Olga Meulenbroek; Aysun Cetinyurek-Yavuz; John W Sijben; Arend Heerschap; Marcel G M Olde Rikkert
Journal:  Alzheimers Res Ther       Date:  2017-07-26       Impact factor: 6.982

Review 10.  Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?

Authors:  Michael Veitinger; Balazs Varga; Sheila B Guterres; Maria Zellner
Journal:  Acta Neuropathol Commun       Date:  2014-06-16       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.